{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T05:49:29Z","timestamp":1698472169832},"reference-count":72,"publisher":"Japanese Association of Virology","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Uirusu"],"published-print":{"date-parts":[[2016]]},"DOI":"10.2222\/jsv.66.63","type":"journal-article","created":{"date-parts":[[2017,5,8]],"date-time":"2017-05-08T22:06:53Z","timestamp":1494281213000},"page":"63-72","source":"Crossref","is-referenced-by-count":1,"title":["Ebola vaccine, therapeutics, and diagnostics"],"prefix":"10.2222","volume":"66","author":[{"given":"Wakako","family":"FURUYAMA","sequence":"first","affiliation":[{"name":"Hokkaido University Research Center for Zoonosis Control"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayato","family":"TAKADA","sequence":"additional","affiliation":[{"name":"Hokkaido University Research Center for Zoonosis Control"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1062","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Bukreyev AA, Chandran K, Dolnik O, Dye JM, Ebihara H, Leroy EM, Muhlberger E, Netesov SV, Patterson JL, Paweska JT, Saphire EO, Smither SJ, Takada A, Towner JS, Volchkov VE, Warren TK, Kuhn JH. Discussions and decisions of the 2012-2014 International Committee on Taxonomy of Viruses (ICTV) Filoviridae Study Group, January 2012-June 2013. Arch Virol 159:821-830, 2014.","DOI":"10.1007\/s00705-013-1846-9"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Negredo A, Palacios G, V&aacute;zquez-Mor&oacute;n S, Gonz&aacute;lez F, Dopazo H, Molero F, Juste J, Quetglas J, Savji N, de la Cruz Mart&iacute;nez M, Herrera JE, Pizarro M, Hutchison SK, Echevarr&iacute;a JE, Lipkin WI, Tenorio A. Discovery of an ebolavirus-like filovirus in Europe. PLoS Pathog 7:e1002304, 2011.","DOI":"10.1371\/journal.ppat.1002304"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Maruyama J, Miyamoto H, Kajihara M, Ogawa H, Maeda K, Sakoda Y, Yoshida R, Takada A. Characterization of the envelope glycoprotein of a novel filovirus, Lloviu virus. J Virol 88(1): 99-109, 2014.","DOI":"10.1128\/JVI.02265-13"},{"key":"4","unstructured":"4) Report of an International Commission. Ebola haemorrhagic fever in Zaire, 1976. Bulletin of the World Health Organization 56(2):271-293, 1978."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Baize S, Pannetier D, Oestereich L, Rieger T, Koivogui L, Magassouba N, Soropogui B, Sow MS, Ke&iuml;ta S, De Clerck H, Tiffany A, Dominguez G, Loua M, Traor&eacute; A, Koli&eacute; M, Malano ER, Heleze E, Bocquin A, M&eacute;ly S, Raoul H, Caro V, Cadar D, Gabriel M, Pahlmann M, Tappe D, Schmidt-Chanasit J, Impouma B, Diallo AK, Formenty P, Van Herp M, G&uuml;nther S. Emergence of Zaire Ebola virus disease in Guinea. N Eng J Med 371:1418-1425, 2014.","DOI":"10.1056\/NEJMoa1404505"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Takada A, Robison C, Goto H, Sanchez A, Murti KG, Whitt MA, Kawaoka Y. A system for functional analysis of Ebola virus glycoprotein. Proc Natl Acad Sci USA 94:14764-14769, 1997.","DOI":"10.1073\/pnas.94.26.14764"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Volchkov VE, Becker S, Volchkova VA, Ternovoj VA, Kotov AN, Netesov SV, Klenk HD. GP mRNA of Ebola virus is edited by the Ebola virus polymerase and by T7 and vaccinia virus polymerases. Virology 214:421-430, 1995.","DOI":"10.1006\/viro.1995.0052"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Sanchez A, Trappier SG, Mahy BW, Peters CJ, Nichol ST. The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing. Proc Natl Acad Sci USA 93:3602-3607, 1996.","DOI":"10.1073\/pnas.93.8.3602"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Mehedi M, Falzarano D, Seebach J, Hu X, Carpenter MS, Schnittler HJ, Feldmann H. A new Ebola virus nonstructural glycoprotein expressed through RNA editing. J Virol 85:5406-5414, 2011.","DOI":"10.1128\/JVI.02190-10"},{"key":"10","unstructured":"10) Ito H, Watanabe S, Takada A, Kawaoka Y. Ebola virus glycoprotein: proteolytic processing, acylation, cell tropism, and detection of neutralizing antibodies. J Virol 75:1576-1580, 2001."},{"key":"11","unstructured":"11) Takada A. Filovirus tropism: cellular molecules for viral entry. Front Microbiol 3:34, 2012."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Simmons G, Reeves JD, Grogan CC, Vandenberghe LH, Baribaud F, Whitbeck JC, Burke E, Buchmeier MJ, Soilleux EJ, Riley JL, Doms RW, Bates P, P&ouml;hlmann S. DC-SIGN and DC-SIGNR bind ebola glycoproteins and enhance infection of macrophages and endothelial cells. Virology 305:115-123, 2003.","DOI":"10.1006\/viro.2002.1730"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Takada A, Fujioka K, Tsuiji M, Morikawa A, Higashi N, Ebihara H, Kobasa D, Feldmann H, Irimura T, Kawaoka Y. Human macrophage C-type lectin specific for galactose and N-acetylgalactosamine promotes filovirus entry. J Virol 78:2943-2947, 2004.","DOI":"10.1128\/JVI.78.6.2943-2947.2004"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Matsuno K, Nakayama E, Noyori O, Marzi A, Ebihara H, Irimura T, Feldmann H, Takada A. C-type lectins do not act as functional receptors for filovirus entry into cells. Biochem Biophys Res Commun 403:144-148, 2010.","DOI":"10.1016\/j.bbrc.2010.10.136"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Kondratowicz AS, Lennemann NJ, Sinn PL, Davey RA, Hunt CL, Moller-Tank S, Meyerholz DK, Rennert P, Mullins RF, Brindley M, Sandersfeld LM, Quinn K, Weller M, McCray PB Jr, Chiorini J, Maury W. T-cell immunoglobulin and mucin domain 1 (TIM-1) is a receptor for Zaire Ebolavirus and Lake Victoria Marburgvirus. Proc Natl Acad Sci USA 108:8426-8431, 2011.","DOI":"10.1073\/pnas.1019030108"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Jemielity S, Wang JJ, Chan YK, Ahmed AA, Li W, Monahan S, Bu X, Farzan M, Freeman GJ, Umetsu DT, Dekruyff RH, Choe H. TIM-family proteins promote infection of multiple enveloped viruses through virion-associated phosphatidylserine. PLoS Pathog 9:e1003232, 2013.","DOI":"10.1371\/journal.ppat.1003232"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Moller-Tank S, Kondratowicz AS, Davey RA, Rennert PD, Maury W. Role of the phosphatidylserine receptor TIM-1 in enveloped-virus entry. J Virol 87:8327-8341, 2013.","DOI":"10.1128\/JVI.01025-13"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Morizono K., Chen IS. Role of phosphatidylserine receptors in enveloped virus infection. J Virol 88:4275-4290, 2014.","DOI":"10.1128\/JVI.03287-13"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Nanbo A, Imai M, Watanabe S, Noda T, Takahashi K, Neumann G, Halfmann P, Kawaoka Y. Ebolavirus is internalized into host cells via macropinocytosis in a viral glycoprotein-dependent manner. PLoS Pathog 6:e1001121, 2010.","DOI":"10.1371\/journal.ppat.1001121"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Chandran K, Sullivan NJ, Felbor U, Whelan SP, Cunningham JM. Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection. Science 308:1643-1645, 2005.","DOI":"10.1126\/science.1110656"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Brecher M, Schornberg KL, Delos SE, Fusco ML, Saphire EO, White JM. Cathepsin cleavage potentiates the Ebola virus glycoprotein to undergo a subsequent fusion-relevant conformational change. J Virol 86:364-372, 2012.","DOI":"10.1128\/JVI.05708-11"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Miller EH, Obernosterer G, Raaben M, Herbert AS, Deffieu MS, Krishnan A, Ndungo E, Sandesara RG, Carette JE, Kuehne AI, Ruthel G, Pfeffer SR, Dye JM, Whelan SP, Brummelkamp TR, Chandran K. Ebola virus entry requires the host-programmed recognition of an intracellular receptor. EMBO J 31:1947-1960, 2012.","DOI":"10.1038\/emboj.2012.53"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) arette JE, Raaben M, Wong AC, Herbert AS, Obernosterer G, Mulherkar N, Kuehne AI, Kranzusch PJ, Griffin AM, Ruthel G, Dal Cin P, Dye JM, Whelan SP, Chandran K, Brummelkamp TR. Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. Nature 477:340-343, 2011.","DOI":"10.1038\/nature10348"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) C&oacute;t&eacute; M, Misasi J, Ren T, Bruchez A, Lee K, Filone CM, Hensley L, Li Q, Ory D, Chandran K, Cunningham J. Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection. Nature 477:344-348, 2011.","DOI":"10.1038\/nature10380"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) M&uuml;hlberger E, Weik M, Volchkov VE, Klenk HD, Becker S. Comparison of the transcription and replication strategies of marburg virus and Ebola virus by using artificial replication systems. J Virol 73:2333-2342, 1999.","DOI":"10.1128\/JVI.73.3.2333-2342.1999"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Timmins J, Scianimanico S, Schoehn G, Weissenhorn W. Vesicular release of ebola virus matrix protein VP40. Virology 283:1-6, 2001.","DOI":"10.1006\/viro.2001.0860"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Noda T, Sagara H, Suzuki E, Takada A, Kida H, Kawaoka Y. Ebola virus VP40 drives the formation of virus-like filamentous particles along with GP. J Virol 76(10):4855-4865, 2002.","DOI":"10.1128\/JVI.76.10.4855-4865.2002"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Bharat TA, Noda T, Riches JD, Kraehling V, Kolesnikova L, Becker S, Kawaoka Y, Briggs JA. Structural dissection of Ebola virus and its assembly determinants using cryo-electron tomography. Proc Natl Acad Sci USA 109:4275-4280, 2012.","DOI":"10.1073\/pnas.1120453109"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Basler CF, Wang X, M&uuml;hlberger E, Volchkov V, Paragas J, Klenk HD, Garc&iacute;a-Sastre A, Palese P. The Ebola virus VP35 protein functions as a type I IFN antagonist. Proc Natl Acad Sci USA 97:12289-12294, 2000.","DOI":"10.1073\/pnas.220398297"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Reid SP, Leung LW, Hartman AL, Martinez O, Shaw ML, Carbonnelle C, Volchkov VE, Nichol ST, Basler CF. Ebola virus VP24 binds karyopherin alpha1 and blocks STAT1 nuclear accumulation. J Virol 80:5156-5167, 2006.","DOI":"10.1128\/JVI.02349-05"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Valmas C, Grosch MN, Sch&uuml;mann M, Olejnik J, Martinez O, Best SM, Kr&auml;hling V, Basler CF, M&uuml;hlberger E. Marburg virus evades interferon responses by a mechanism distinct from ebola virus. PLoS Pathog 6:e1000721, 2010.","DOI":"10.1371\/journal.ppat.1000721"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Nakayama E, Takada A. Ebola and Marburg Viruses. J Disaster Res 6:381-389, 2011.","DOI":"10.20965\/jdr.2011.p0381"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ. Development of a preventive vaccine for Ebola virus infection in primates. Nature 408:605-609, 2000.","DOI":"10.1038\/35046108"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Jones SM, Feldmann H, Str&ouml;her U, Geisbert JB, Fernando L, Grolla A, Klenk HD, Sullivan NJ, Volchkov VE, Fritz EA, Daddario KM, Hensley LE, Jahrling PB, Geisbert TW. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med 11:786-790, 2005.","DOI":"10.1038\/nm1258"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Bukreyev A, Rollin PE, Tate MK, Yang L, Zaki SR, Shieh WJ, Murphy BR, Collins PL, Sanchez A. Successful topical respiratory tract immunization of primates against Ebola virus. J Virol 81:6379-6388, 2007.","DOI":"10.1128\/JVI.00105-07"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Herbert AS, Kuehne AI, Barth JF, Ortiz RA, Nichols DK, Zak SE, Stonier SW, Muhammad MA, Bakken RR, Prugar LI, Olinger GG, Groebner JL, Lee JS, Pratt WD, Custer M, Kamrud KI, Smith JF, Hart MK, Dye JM. Venezuelan equine encephalitis virus replicon particle vaccine protects nonhuman primates from intramuscular and aerosol challenge with ebolavirus. J Virol 87:4952-4964, 2013.","DOI":"10.1128\/JVI.03361-12"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Blaney JE, Marzi A, Willet M, Papaneri AB, Wirblich C, Feldmann F, Holbrook M, Jahrling P, Feldmann H, Schnell MJ. Antibody quality and protection from lethal Ebola virus challenge in nonhuman primates immunized with Rabies virus based bivalent vaccine. PLoS Pathog 9:e1003389, 2013.","DOI":"10.1371\/journal.ppat.1003389"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Feldmann H, Jones SM, Daddario-DiCaprio KM, Geisbert JB, Str&ouml;her U, Grolla A, Bray M, Fritz EA, Fernando L, Feldmann F, Hensley LE, Geisbert TW. Effective post-exposure treatment of Ebola infection. PLoS Pathog 3:e2, 2007.","DOI":"10.1371\/journal.ppat.0030002"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Geisbert TW, Hensley LE, Geisbert JB, Leung A, Johnson JC, Grolla A, Feldmann H. Postexposure treatment of Marburg virus infection. Emerg Infect Dis 16:1119-1122, 2010.","DOI":"10.3201\/eid1607.100159"},{"key":"40","unstructured":"40) Rampling T, Ewer K, Bowyer G, Wright D, Imoukhuede EB, Payne R, Hartnell F, Gibani M, Bliss C, Minhinnick A, Wilkie M, Venkatraman N, Poulton I, Lella N, Roberts R, Sierra-Davidson K, Kr&auml;hling V, Berrie E, Roman F, De Ryck I, Nicosia A, Sullivan NJ, Stanley DA, Ledgerwood JE, Schwartz RM, Siani L, Colloca S, Folgori A, Di Marco S, Cortese R, Becker S, Graham BS, Koup RA, Levine MM, Moorthy V, Pollard AJ, Draper SJ, Ballou WR, Lawrie A, Gilbert SC, Hill AV. A monovalent chimpanzee adenovirus Ebola vaccine - Preliminary Report. N Eng J Med (in press)."},{"key":"41","unstructured":"41) ClinicalTrials.gov. A study to find out if the new Ebola vaccine is safe and stimulates immunity that might protect adults in Kilifi, Kenya. https:\/\/www.clinicaltrials.gov\/ct2\/show\/study\/NCT02296983, 2015."},{"key":"42","unstructured":"42) Ebola test vaccines appear safe in Phase 2 Liberian clinical trial. http:\/\/www.nih.gov\/news\/health\/mar2015\/niaid-26a.htm, 2015."},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Henao-Restrepo AM, Longini IM, Egger M, Dean NE, Edmunds WJ, Camacho A, Carroll MW, Doumbia M, Draguez B, Duraffour S, Enwere G, Grais R, Gunther S, Hossmann S, Kond&eacute; MK, Kone S, Kuisma E, Levine MM, Mandal S, Norheim G, Riveros X, Soumah A, Trelle S, Vicari AS, Watson CH, K&eacute;&iuml;ta S, Kieny MP, Rcitation=66) Qiu X, Wong G, Audet J, Bello A, Fernando L, Alimonti JB, Fausther-Bovendo H, Wei H, Aviles J, Hiatt E, Johnson A, Morton J, Swope K, Bohorov O, Bohorova N, Goodman C, Kim D, Pauly MH, Velasco J, Pettitt J, Olinger GG, Whaley K, Xu B, Strong JE, Zeitlin L, Kobinger GP. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 514:47-53, 2014.","DOI":"10.1038\/nature13777"},{"key":"44","doi-asserted-by":"crossref","unstructured":"67) McCarthy M. US signs contract with ZMapp maker to accelerate development of the Ebola drug. BMJ 349:g5488, 2014.","DOI":"10.1136\/bmj.g5488"},{"key":"45","unstructured":"68) ClinicalTrials.gov. Safety and pharmacokinetics of a single ZMappTM administration in healthy adult volunteers. https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT02389192, 2016."},{"key":"46","doi-asserted-by":"crossref","unstructured":"69) Furuyama W, Marzi A, Nanbo A, Haddock E, Maruyama J, Miyamoto H, Igarashi M, Yoshida R, Noyori O, Feldmann H, Takada A. Discovery of an antibody for pan-ebolavirus therapy. Sci Rep 6:20514, 2016.","DOI":"10.1038\/srep20514"},{"key":"47","unstructured":"70) Holtsberg FW, Shulenin S, Vu H, Howell KA, Patel SJ, Gunn B, Karim M, Lai JR, Frei JC, Nyakatura EK, Zeitlin L, Douglas R, Fusco ML, Froude JW, Saphire EO, Herbert AS, Wirchnianski AS, Lear-Rooney CM, Alter G, Dye JM, Glass PJ, Warfield KL, Aman MJ. Pan-ebolavirus and Pan-filovirus mouse monoclonal antibodies: protection against Ebola and Sudan viruses. J Virol 90:266-278, 2016."},{"key":"48","doi-asserted-by":"crossref","unstructured":"71) Flyak Andrew I, Shen X, Murin Charles D, Turner Hannah L, David Joshua A, Fusco Marnie L, Lampley R, Kose N, Ilinykh Philipp A, Kuzmina N, Branchizio A, King H, Brown L, Bryan C, Davidson E, Doranz Benjamin J, Slaughter James C, Sapparapu G, Klages C, Ksiazek Thomas G, Saphire Erica O, Ward Andrew B, Bukreyev A, Crowe Jr James E. Cross-reactive and potent neutralizing antibody responses in human survivors of natural ebolavirus infection. Cell 164:392-405, 2016.","DOI":"10.1016\/j.cell.2015.12.022"},{"key":"49","doi-asserted-by":"crossref","unstructured":"72) Furuta Y, Takahashi K, Kuno-Maekawa M, Sangawa H, Uehara S, Kozaki K, Nomura N, Egawa H, Shiraki K. Mechanism of action of T-705 against influenza virus. Antimicrob Agents Chemother 49:981-986, 2005.","DOI":"10.1128\/AAC.49.3.981-986.2005"},{"key":"50","doi-asserted-by":"crossref","unstructured":"73) Sangawa 1, Komeno T, Nishikawa H, Yoshida A, Takahashi K, Nomura N, Furuta Y. Mechanism of action of T-705 ribosyl triphosphate against influenza virus RNA polymerase. Antimicrob Agents Chemother 57:5202-5208, 2013.","DOI":"10.1128\/AAC.00649-13"},{"key":"51","doi-asserted-by":"crossref","unstructured":"74) Smither SJ, Eastaugh LS, Steward JA, Nelson M, Lenk RP, Lever MS. Postexposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model. Antiviral Res 104:153-155, 2014.","DOI":"10.1016\/j.antiviral.2014.01.012"},{"key":"52","doi-asserted-by":"crossref","unstructured":"75) Oestereich L, Ludtke A, Wurr S, Rieger T, Munoz-Fontela C, Gunther S. Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antiviral Res 105:17-21, 2014.","DOI":"10.1016\/j.antiviral.2014.02.014"},{"key":"53","unstructured":"76) ClinicalTrials.gov. Efficacy of Favipiravir against severe Ebola virus disease. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02662855, 2016."},{"key":"54","unstructured":"77) Press Releases. BioCryst Pharmaceuticals Inc. BioCryst announces study results for BCX4430 in a non-human primate model of Ebola virus infection. http:\/\/investor.shareholder.com\/biocryst\/releasedetail.cfm?ReleaseID=888802, 2015."},{"key":"55","doi-asserted-by":"crossref","unstructured":"78) Warren TK, Wells J, Panchal RG, Stuthman KS, Garza NL, Van Tongeren SA, Dong L, Retterer CJ, Eaton BP, Pegoraro G, Honnold S, Bantia S, Kotian P, Chen X, Taubenheim BR, Welch LS, Minning DM, Babu YS, Sheridan WP, Bavari S. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature 508:402-405, 2014.","DOI":"10.1038\/nature13027"},{"key":"56","unstructured":"79) Geisbert TW, Lee AC, Robbins M, Geisbert JB, Honko AN, Sood V, Johnson JC, de Jong S, Tavakoli I, Judge A, Hensley LE, Maclachlan I. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet 375:1896-1905, 2010."},{"key":"57","doi-asserted-by":"crossref","unstructured":"80) Iversen PL, Warren TK, Wells JB, Garza NL, Mourich DV, Welch LS, Panchal RG, Bavari S. Discovery and early development of AVI-7537 and AVI-7288 for the treatment of Ebola virus and Marburg virus infections. Viruses 4:2806-2830, 2012.","DOI":"10.3390\/v4112806"},{"key":"58","doi-asserted-by":"crossref","unstructured":"81) Warren TK, Warfield KL, Wells J, Swenson DL, Donner KS, Van Tongeren SA, Garza NL, Dong L, Mourich DV, Crumley S, Nichols DK, Iversen PL, Bavari S. Advanced antisense therapies for postexposure protection against lethal filovirus infections. Nat Med 16:991-994, 2010.","DOI":"10.1038\/nm.2202"},{"key":"59","unstructured":"82) Heald AE, Iversen PL, Saoud JB, Sazani P, Charleston JS, Axtelle T, Wong M, Smith WB, Vutikullird A, Kaye E. Safety and pharmacokinetic profiles of phosphorodiamidate morpholino oligomers with activity against Ebola virus and Marburg virus: Results of two single-ascending-dose studies. Antimicrob Agents Chemother 58:6639-6647, 2014."},{"key":"60","doi-asserted-by":"crossref","unstructured":"83) Jahrling PB, Geisbert TW, Geisbert JB, Swearengen JR, Bray M, Jaax NK, Huggins JW, LeDuc JW, Peters CJ. Evaluation of immune globulin and recombinant interferon-&alpha;2b for treatment of experimental Ebola virus infections. J Infect Dis 179 Suppl 1:S224-S234, 1999.","DOI":"10.1086\/514310"},{"key":"61","doi-asserted-by":"crossref","unstructured":"84) Smith LM, Hensley LE, Geisbert TW, Johnson J, Stossel A, Honko A, Yen JY, Geisbert J, Paragas J, Fritz E, Olinger G, Young HA, Rubins KH, Karp CL. Interferon-&beta; therapy prolongs survival in rhesus macaque nodels of Ebola and Marburg hemorrhagic fever. J Infect Dis 208:310-318, 2013.","DOI":"10.1093\/infdis\/jis921"},{"key":"62","unstructured":"85) Cohen J, Enserink M. Special report: Ebola's thin harvest. Science News http:\/\/www.sciencemag.org\/news\/2015\/12\/special-report-ebolas-thin-harvest, 2015."},{"key":"63","doi-asserted-by":"crossref","unstructured":"86) Rhein BA, Powers LS, Rogers K, Anantpadma M, Singh BK, Sakurai Y, Bair T, Miller-Hunt C, Sinn P, Davey RA, Monick MM, Maury W. Interferon-&gamma; inhibits Ebola virus infection. PLoS Pathog 11:e1005263, 2015.","DOI":"10.1371\/journal.ppat.1005263"},{"key":"64","unstructured":"87) World Health Organization. Laboratory diagnosis of Ebola virus disease. http:\/\/apps.who.int\/iris\/bitstream\/10665\/134009\/1\/WHO_EVD_GUIDANCE_LAB_14.1_eng.pdf, 2014."},{"key":"65","unstructured":"88) World Health Organization. WHO Emergency Quality Assessment Mechanism for EVD IVDs. Product: RealStar&reg; Filovirus Screen RT-PCR Kit 1.0 http:\/\/www.who.int\/diagnostics_laboratory\/procurement\/141125_evd_public_report_altona_v1.pdf?ua=1, 2015."},{"key":"66","unstructured":"89) World Health Organization. WHO emergency use assessment and listing procedure for EVD IVDs. Product: Liferiver<sup>TM<\/sup> - Ebola Virus (EBOV) Real Time RT-PCR Kit. http:\/\/www.who.int\/diagnostics_laboratory\/procurement\/150427_liferiver_china_public_report.pdf, 2015."},{"key":"67","unstructured":"90) World Health Organization. WHO emergency use assessment and listing for EVD IVDs. Product: Xpert&reg; Ebola Assay. http:\/\/www.who.int\/medicines\/ebola-treatment\/150508FinalPublicReportExpertEbola_Cepheid.pdf, 2015."},{"key":"68","unstructured":"91) World Health Organization. WHO emergency use assessment and listing for Ebola virus disease IVDs. Product: ReEBOV<sup>TM<\/sup> Antigen Rapid Test Kit http:\/\/www.who.int\/diagnostics_laboratory\/procurement\/150219_reebov_antigen_rapid_test_public_report.pdf?ua=1, 2015."},{"key":"69","unstructured":"92) Broadhurst MJ, Kelly JD, Miller A, Semper A, Bailey D, Groppelli E, Simpson A, Brooks T, Hula S, Nyoni W, Sankoh AB, Kanu S, Jalloh A, Ton Q, Sarchet N, George P, Perkins MD, Wonderly B, Murray M, Pollock NR. ReEBOV Antigen Rapid Test kit for point-of-care and laboratory-based testing for Ebola virus disease: a field validation study. Lancet 386:867-874, 2015."},{"key":"70","unstructured":"93) Food and Drug Administration. Ebola virus emergency use authorizations. http:\/\/www.fda.gov\/medicaldevices\/safety\/emergencysituations\/ucm161496.htm#ebola, 2014."},{"key":"71","unstructured":"94) World Health Organization. WHO emergency use assessment and listing for Ebola virus disease IVDs. Product: OraQuick&reg; Ebola Rapid Antigen Test Kit. http:\/\/www.who.int\/diagnostics_laboratory\/160324_final_public_report_ea_0023_021_00.pdf?ua=1, 2016."},{"key":"72","unstructured":"95) Corgenix. ReEBOV Antigen Rapid Test (Ebolavirus VP40 antigen detection) instructions for use. ftp:\/\/ftp.corgenix.com\/Intra\/ReEBOV\/14005.pdf, 2015."}],"container-title":["Uirusu"],"original-title":["\u30a8\u30dc\u30e9\u51fa\u8840\u71b1\u306e\u4e88\u9632\u30fb\u6cbb\u7642\u30fb\u8a3a\u65ad\u6cd5\u958b\u767a\u306e\u73fe\u72b6"],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jsv\/66\/1\/66_63\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T04:09:26Z","timestamp":1602043766000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jsv\/66\/1\/66_63\/_article\/-char\/ja\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":72,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.2222\/jsv.66.63","relation":{},"ISSN":["0042-6857","1884-3433"],"issn-type":[{"value":"0042-6857","type":"print"},{"value":"1884-3433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}